Meeting
2014 ASCO Annual Meeting
A phase I study of cabozantinib (XL184) in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: A Children’s Oncology Group phase I consortium trial.
Authors
Meredith K. Chuk
Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD
Meredith K. Chuk , Brigitte C. Widemann , Charlotte H. Ahern , Joel M. Reid , AeRang Kim , John Joseph Wright , Maya Lodish , Elizabeth Fox , Brenda Weigel , Susan Blaney
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Pediatric Solid Tumors
Clinical Trial Registration Number
NCT01709435
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 10078)
DOI
10.1200/jco.2014.32.15_suppl.10078
Abstract #
10078
Poster Bd #
379
Abstract Disclosures
Similar Posters
First Author: Stuart Cramer
Poster
2021 ASCO Annual Meeting
Phase 1 study of pevonedistat (MLN4924) a NEDD8 activating enzyme inhibitor, in combination with temozolomide (TMZ) and irinotecan (IRN) in pediatric patients with recurrent or refractory solid tumors (ADVL1615).
First Author: Jennifer Foster
Poster
2018 ASCO Annual Meeting
ADVL1513: Results of a phase 1 trial of entinostat, an oral histone deacetylase inhibitor, in pediatric patients with recurrent or refractory solid tumors.
First Author: Suman Malempati
Poster
2016 ASCO Annual Meeting
Phase I dose-escalation and pharmacokinetic (PK) study of regorafenib in pediatric patients with recurrent or refractory solid malignancies.
First Author: Birgit Geoerger